TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.080
-0.010 (-0.92%)
At close: Dec 5, 2025, 4:00 PM EST
1.090
+0.010 (0.94%)
After-hours: Dec 5, 2025, 7:55 PM EST
TScan Therapeutics Stock Forecast
TCRX's stock price has decreased by -75.73% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 6 analysts with 12-month price forecasts for TScan Therapeutics stock have an average target of 8.50, with a low estimate of 3.00 and a high estimate of 15. The average target predicts an increase of 687.04% from the current stock price of 1.08.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for TScan Therapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $10 → $7 | Strong Buy | Maintains | $10 → $7 | +548.15% | Nov 13, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 4, 2025 |
| Needham | Needham | Strong Buy Maintains $9 → $6 | Strong Buy | Maintains | $9 → $6 | +455.56% | Nov 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $10 | Strong Buy | Maintains | $15 → $10 | +825.93% | May 7, 2025 |
| Needham | Needham | Strong Buy Reiterates $9 | Strong Buy | Reiterates | $9 | +733.33% | Apr 8, 2025 |
Financial Forecast
Revenue This Year
10.89M
from 2.82M
Increased by 286.83%
Revenue Next Year
10.44M
from 10.89M
Decreased by -4.12%
EPS This Year
-1.10
from -2.25
EPS Next Year
-0.96
from -1.10
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 15.8M | 25.4M | ||||
| Avg | 10.9M | 10.4M | ||||
| Low | 8.1M | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 459.3% | 133.1% | ||||
| Avg | 286.8% | -4.1% | ||||
| Low | 188.8% | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.06 | -0.69 | ||||
| Avg | -1.10 | -0.96 | ||||
| Low | -1.11 | -1.45 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.